Global Animal Stem Cell Therapy Market Research Report by Size, Data, Developments, Global Demand, In-Depth Analysis and Forecast 2020 to 2025 |…

Global Animal Stem Cell Therapy Market

Global Animal Stem Cell Therapy Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Global Animal Stem Cell Therapy market.

Global Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2025. The increasing interest of the individuals in this industry is the major reason for the expansion of this market.

Key Market Players: MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics.

Request for Sample Copy of this report: (SPECIAL OFFER: UP TO 25% DISCOUNT FOR A LIMITED TIME)

https://www.theresearchinsights.com/request_sample.php?id=284577

Market Segmentation by Types:

Dogs

Horses

Others

Market Segmentation by Applications:

Veterinary Hospitals

Research Organizations

Additionally, the market report has a devoted segment covering the current market players from the Global Animal Stem Cell Therapy Market. A concise profile section similarly fuses the business system and capital-related information so that capital-related decisions can be recommended to the clients effectively.

Buy Exclusive Report:

https://www.theresearchinsights.com/checkout?id=284577

Important Facts about Global Animal Stem Cell Therapy Market Report:

This research report encompasses Global Animal Stem Cell Therapy Market overview, market share, demand and supply ratio, supply chain analysis, and import/export details.

The report has different approaches and procedures endorsed by Key Market players that enable efficient business decisions.

The report offers information such as production value, strategies adopted by market players and products/services they provide.

Click Below to Get Full Report and Related Details:https://www.theresearchinsights.com/reports/COVID19-Version-Global-Animal-Stem-Cell-Therapy-Market-Status-20152019-and-Forecast-20202025-by-Region-Product-TypeEndUse-284577

What Our Report Offers:

Market share valuations of the segments on country and global level

Share analysis of the major market players

Opportunities for new market entrants

Market forecast for a minimum of 6 years for all the segments, sub-segments in various countries and regions

Market Trends (drivers, restraints, opportunities, threats, challenges, investment opportunities, and approvals)

Strategic endorsements in key business segments on the basis of market valuations

Competitive scenario mapping the key development patterns.

Company profiling with comprehensive strategies, financial details, and recent progressions.

Supply chain trends representing the latest technological advancements.

About us:

The Research Insights is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. The Research Insights offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials, and much more.

Contact us:

Robin (Head of Sales) The Research Insights

Phone: +91-996-067-0000 | +44-753-718-0101 | +1-312-313-8080

[emailprotected] | https://www.theresearchinsights.com

Continue reading here:

Global Animal Stem Cell Therapy Market Research Report by Size, Data, Developments, Global Demand, In-Depth Analysis and Forecast 2020 to 2025 |...

Read more
The Thorough Analysis Of The Global Stem Cell Media market Research During COVID-19 Health Crisis – The Courier

A new independent global Stem Cell Media Market research report by retailer name is a perfect blend of qualitative and quantitative data to make better informed evaluation to analyze competition. The report covers geographic evaluation that comprises areas such as Europe, North America, South America, Asia-Pacific, and essential vendors/players such as Players With number of figures and tables examining the Stem Cell Media market, the study offers you a one-stop, visual breakdown of the leading submarkets, products, and market leaders market revenue prediction as well as evaluation for the years to come.

Check discount and get customization for global Stem Cell Media market research report @ https://spiremarketresearch.com/report/covid19-impact-stem-cell-media-market-295559#inquiry-for-buying

The objective of the global Stem Cell Media market research report is to define market sizes of various countries and segments in recent years and to predict the values to the years to come. The report is developed to incorporate both quantitative and qualitative factors of the market within each of the countries and areas comprised in the global Stem Cell Media market research report. In addition to this, the report also caters the detailed data about the essential factors such as challenges and driving factors which will define the future development of the market. Moreover, the global Stem Cell Media market research report shall also contain available opportunities in micro markets for stakeholders to invest together with the comprehensive study of product offerings and competitive landscape of major players. The detailed sections and sub-sections of the market are explained in the global Stem Cell Media market research report.

The global Stem Cell Media market research report includes qualitative commentary and exploratory survey on changing market dynamics with market estimates and sizing for business segments, global countries, and applications. The identification of emerging players is completed by listing some of the major industry players.

Thermo FisherSTEMCELL TechnologiesMerck MilliporeLonzaGE HealthcareMiltenyi BiotecCorningCellGenixTakaraPromoCell

The Stem Cell Media

Get inside scoop of the global Stem Cell Media market research report, request for sample @: https://spiremarketresearch.com/report/covid19-impact-stem-cell-media-market-295559#request-sample

Recent analysis shows high development emerging leaders and players by market share that are presently attracting exceptional attention. It also motivates managers and executives to study deeply complementary research metric. The evaluations also provide insight into the size and share of different segments in the global -Stem Cell Media market. The scope of the global Stem Cell Media market research report includes market break-up or segmentation too.

Early buyers are entitled to get discount on standard edition or customization on reports at no added cost. Get more details @ https://spiremarketresearch.com/report/covid19-impact-stem-cell-media-market-295559#inquiry-for-buying

The global Stem Cell Media market research report mentions examples of different market business strategies and development activities that industry players are accepting to overcome economic challenges and to match demand supply gap. A detailed main business information, company profile, sales, SWOT analysis, average price, revenue, % market share of select players, and gross margin would be available in the global Stem Cell Media market research report.

The study also contains the major strategic developments of the market, including new product launch, R&D, agreements, M&A, partnerships, collaborations, regional growth, and joint ventures of the leading competitors active in the market on a regional and global scale.

Continue reading here:

The Thorough Analysis Of The Global Stem Cell Media market Research During COVID-19 Health Crisis - The Courier

Read more
Circulating Tumor Cells and Cancer Stem Cells Market Research Report 2020 with Manufacturing Process Analysis and Market Concentration Rate till 2026…

The Circulating Tumor Cells and Cancer Stem Cells Market grew in 2019, as compared to 2018, according to our report, Circulating Tumor Cells and Cancer Stem Cells Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Circulating Tumor Cells and Cancer Stem Cells Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Circulating Tumor Cells and Cancer Stem Cells Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-circulating-tumor-cells-and-cancer-stem-cells-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Circulating Tumor Cells and Cancer Stem Cells Market is analysed based on product types, major applications and key players

Key product type:Cell EnrichmentDetectionCTC Analysis

Key applications:HospitalNSCMedical Research Institute

Key players or companies covered are:QIAGEN HannoverAVIVA BiosciencesEpic SciencesApoCellCynvenio BiosystemsFluxion BiosciencesRarecellsJanssen DiagnosticsCellTraffixSilicon BiosystemsAdvanced Cell Diagnostics

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-circulating-tumor-cells-and-cancer-stem-cells-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Circulating Tumor Cells and Cancer Stem Cells Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Circulating Tumor Cells and Cancer Stem Cells Market?4. What is the likely market forecast & how will be Circulating Tumor Cells and Cancer Stem Cells Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Circulating Tumor Cells and Cancer Stem Cells Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

Read the original:

Circulating Tumor Cells and Cancer Stem Cells Market Research Report 2020 with Manufacturing Process Analysis and Market Concentration Rate till 2026...

Read more
Europe Cell Therapy Instruments Market Forecast to 2027 – Covid-19 Impact and Regional Analysis – By Product ; Cell Type ; Process ; End User, and…

New York, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Cell Therapy Instruments Market Forecast to 2027 - Covid-19 Impact and Regional Analysis - By Product ; Cell Type ; Process ; End User, and Country" - https://www.reportlinker.com/p05989522/?utm_source=GNW

The surge in the number of cell therapy transplantation procedures, growing research and development activities, and rising investments in building production facilities for cell and gene therapy products drive the growth of the Europe cell therapy instruments market. However, the low success rate of cell therapies and the high cost of cell-based research is expected to restrain the market growth during the forecast period.

Cell therapy typically involves the administration of somatic cell preparations by injecting or grafting it into the patients body for the treatment of diseases or traumatic damages.The procedure is used to cure diabetes, neurological disorders, related injuries, several cancer types, bones and joints, and genetic disorders.

Continuous research and development activities have led to unique cell therapeutic instruments for the improvement of immune system and efficient treatment of genetic disorders. Various market players provide several consumables such as reagent kits and enzymes as well as devices, equipment, and software to perform various cell therapy processes.

The use of instruments is essential for handling cell therapies such as NSC, PSC, MSC, T cells, and HSC.These cell therapy products are derived from animals or human cells and thus need to be protected from contamination.

The instruments used in cell therapies help provide protection against contamination and allow scaling up of transplantation. Companies such as Hitachi Chemical Advanced Therapeutics Solutions; Corning Incorporated; Thermo Fisher Scientific Inc.; MiltenyiBiotec, LLC; Invetech; and Cytiva (General Electric Company) have introduced various equipment and consumables for the cell therapy procedures.

The cell therapy instrument market witnessed staggered growth at the beginning of COVID 19 crisis owing to factors such as disruption in supply chain and lowered demand for cell therapies due to lock down announced by majority of European countries. However, in long term, the demand for the cell therapy instruments is expected to increase owing to supportive government initiatives in European countries.

On the basis of product, the Europe cell therapy instruments market is further segmented into consumables, software, equipment, and systems.The consumables segment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.

The Europe cell therapy instruments market, based on cell type, is segmented into animal cells and human cells. The human cells segment held a larger share of the market in 2019 and is estimated to register a higher CAGR during 20202027.

The Europe cell therapy instruments market, based on process, is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control.The cell processing segment held the larger share of the market in 2019 and is estimated to register the highest CAGR from 2020 to 2027.

Based on end user, the Europe cell therapy instruments market is segmented into life science research companies, research institutes, and other end users. The life science research companies grasped the largest share of the market in 2019, and the same segment is anticipated to register the highest CAGR during the forecast period.

A few of the major primary and secondary sources referred to while preparing this report on the Europe cell therapy instruments market include National Center for Biotechnology Information (NCBI); World Health Organization (WHO); European Commission (EC); and Global Institute of Stem Cell Therapy and Research (GIOSTAR).Read the full report: https://www.reportlinker.com/p05989522/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original post:

Europe Cell Therapy Instruments Market Forecast to 2027 - Covid-19 Impact and Regional Analysis - By Product ; Cell Type ; Process ; End User, and...

Read more
Asia Pacific Cell Therapy Instruments Market Forecast to 2027 – Covid-19 Impact and Regional Analysis – By Product ; Cell Type ; Process ; End User,…

New York, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Cell Therapy Instruments Market Forecast to 2027 - Covid-19 Impact and Regional Analysis - By Product ; Cell Type ; Process ; End User, and Country" - https://www.reportlinker.com/p05989496/?utm_source=GNW However, the low success rate of cell therapies and the high cost of cell-based research is expected to restrain the market growth during the forecast period.

Cell therapy typically involves the administration of somatic cell preparations by injecting or grafting it into the patients body for the treatment of diseases or traumatic damages.The procedure is used to cure diabetes, neurological disorders, related injuries, several cancer types, bones and joints, and genetic disorders.

Continuous research and development activities have led to unique cell therapeutic instruments for the improvement of immune system and efficient treatment of genetic disorders. Various market players provide several consumables such as reagent kits and enzymes as well as devices, equipment, and software to perform various cell therapy processes.

The use of instruments is essential for handling cell therapies such as NSC, PSC, MSC, T cells, and HSC.These cell therapy products are derived from animals or human cells and thus need to be protected from contamination.

The instruments used in cell therapies help provide protection against contamination and allow scaling up of transplantation. Companies such as Hitachi Chemical Advanced Therapeutics Solutions Corning Incorporated; Thermo Fisher Scientific Inc., MiltenyiBiotec, LLC; Invetech; and Cytiva (General Electric Company) have introduced various equipment and consumables for the cell therapy procedures.

The global COVID-19 emergency has been particularly affecting the supply chain worldwide.The supply chain disruptions, along with the enormous demand for effective therapies for the treatment of COVID-19, have put the healthcare research industry in a crucial situation in the Asia Pacific region.

However, many medical companies have realized the importance of cell therapy in the treatment of COVID 19, which would raise its demand in the coming years.

The Asia Pacific cell therapy instruments market, by product, is segmented into consumables, software, equipment, and systems.The consumables segment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.

On the basis of cell type, the cell therapy instruments market is segmented into animal cells and human cells. The human cells segment held a larger share of the market in 2019 and is estimated to register a higher CAGR during the forecast period.

On the basis of process, the Asia Pacific cell therapy instruments market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control.The cell processing segment held the largest share of the market in 2019 and is estimated to register the highest CAGR during the forecast period.

The Asia Pacific cell therapy instruments market, based on end user, is segmented into life science research companies, research institutes, and other end users. The life science research companies segment accounted for the largest share of the market in 2019 and is anticipated to register the highest CAGR during the forecast period.

A few of the major primary and secondary sources associated with the Asia Pacific cell therapy instruments market are National Center for Biotechnology Information (NCBI); World Health Organization (WHO); Medical Research Future Fund (MRFF); Asia-Pacific Economic Corporation (APEC); and Global Institute of Stem Cell Therapy and Research (GIOSTAR).Read the full report: https://www.reportlinker.com/p05989496/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original post:

Asia Pacific Cell Therapy Instruments Market Forecast to 2027 - Covid-19 Impact and Regional Analysis - By Product ; Cell Type ; Process ; End User,...

Read more
Adherence to Allogeneic Stem Cell Transplantation to Improve Survival in Myelodysplastic Syndromes – Hematology Advisor

With the exception of allogeneic stem cell transplantation (alloSCT) and iron chelation therapy (ICT), many guideline treatments may not improve survival among patients with myelodysplastic syndrome (MDS), according to research published in the Annals of Hematology.

MDS represents a heterogeneous group of malignancies with a variable clinical course, which depends on both disease and patient factors. A number of guidelines help clinicians to recommend treatments based on these characteristics, including European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN).

It is unknown whether adherence to guideline recommendations improves survival in this patient group. For this study, which had a retrospective cohort and prospective cohort, researchers evaluated whether treatment guideline adherence improves survival among patients with MDS.

All data were obtained from the Duesseldorf MDS Registry. Cohort 1 included data from 1698 patients, to which the researchers applied ELN guidelines retrospectively. Cohort 2 included patients who were given expert-level guidance on MDS treatment.

Overall, in cohort 1, of the treatment options evaluated, adherence to lenalidomide, hypomethylating agents, low-dose chemotherapy, intensive chemotherapy, or best supportive care therapies did not improve patient survival; similar results were found in analyses of cohort 2.

Patients receiving ICT or alloSCT in line with expert guidelines did, however, appear to have improved survival compared with those who were eligible for such treatments but did not receive them. The median survival of patients who were recommended and received ICT was 70 months vs 32 months for eligible patients who did not receive ICT (P =.012). In addition, the median survival for alloSCT-eligible patients who received transplantation compared with patients who did not receive transplantation was 65 months vs 16 months, respectively (P <.0005).

Altogether, our retrospective and prospective analyses imply that, with the exception of alloSCT, none of the currently available therapies is powerful enough to render deviation from guideline-based expert advice a major disadvantage in terms of prognosis, the authors wrote. We clearly need better treatment options, which can really make a change when correctly applied by an MDS expert.

Disclosures: Some authors have declared affiliations with or received funding from the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Kasprzak A, Nachtkamp K, Kondakci M, et al. Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes. Ann Hematol. Published online November 7, 2020. doi:10.1007/s00277-020-04325-7

Go here to see the original:

Adherence to Allogeneic Stem Cell Transplantation to Improve Survival in Myelodysplastic Syndromes - Hematology Advisor

Read more
Cutting edge technology used to bioprint miniature human kidneys in the lab – News-Medical.Net

Researchers have used cutting edge technology to bioprint miniature human kidneys in the lab, paving the way for new treatments for kidney failure and possibly lab-grown transplants.

The study, led by the Murdoch Children's Research Institute (MCRI) and biotech company Organovo and published in Nature Materials, saw the research team also validate the use of 3D bioprinted human mini kidneys for screening of drug toxicity from a class of drugs known to cause kidney damage in people.

The research showed how 3D bioprinting of stem cells can produce large enough sheets of kidney tissue needed for transplants.

Like squeezing toothpaste out of a tube, extrusion-based 3D bioprinting uses a 'bioink' made from a stem cell paste, squeezed out through a computer-guided pipette to create artificial living tissue in a dish.

MCRI researchers teamed up with San Diego-based Organovo Inc to create the mini organs.

MCRI Professor Melissa Little, a world leader in modeling the human kidney, first began growing kidney organoids in 2015. But this new bio-printing method is faster, more reliable and allows the whole process to be scaled up. 3D bioprinting could now create about 200 mini kidneys in 10 minutes without compromising quality, the study found.

From larger than a grain of rice to the size of a fingernail, bioprinted mini-kidneys fully resemble a regular-sized kidney, including the tiny tubes and blood vessels that form the organ's filtering structures called nephrons.

Professor Little said by using mini-organs her team hope to screen drugs to find new treatments for kidney disease or to test if a new drug was likely to injure the kidney.

Drug-induced injury to the kidney is a major side effect and difficult to predict using animal studies. Bioprinting human kidneys are a practical approach to testing for toxicity before use."

Melissa Little, MCRI Professor

In this study, the toxicity of aminoglycosides, a class of antibiotics that commonly damage the kidney, were tested.

"We found increased death of particular types of cells in the kidneys treated with aminoglycosides," Professor Little said.

"By generating stem cells from a patient with a genetic kidney disease, and then growing mini kidneys from them, also paves the way for tailoring treatment plans specific to each patient, which could be extended to a range of kidney diseases."

Professor Little said the study showed growing human tissue from stem cells also brought the promise of bioengineered kidney tissue.

"3D bioprinting can generate larger amounts of kidney tissue but with precise manipulation of biophysical properties, including cell number and conformation, improving the outcome," she said.

Currently, 1.5 million Australians are unaware they are living with early signs of kidney disease such as decreased urine output, fluid retention and shortness of breath.

Professor Little said prior to this study the possibility of using mini kidneys to generate transplantable tissue was too far away to contemplate.

"The pathway to renal replacement therapy using stem cell-derived kidney tissue will need a massive increase in the number of nephron structures present in the tissue to be transplanted," she said.

"By using extrusion bioprinting, we improved the final nephron count, which will ultimately determine whether we can transplant these tissues into people."

Source:

Journal reference:

Lawlor, K.T., et al. (2020) Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation. Nature Materials. doi.org/10.1038/s41563-020-00853-9.

Read this article:

Cutting edge technology used to bioprint miniature human kidneys in the lab - News-Medical.Net

Read more
Scaffold Technology Market Research Report by Product, by Application, by End-User – Global Forecast to 2025 – Cumulative Impact of COVID-19 -…

New York, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Scaffold Technology Market Research Report by Product, by Application, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05989770/?utm_source=GNW

The Global Scaffold Technology Market is expected to grow from USD 868.36 Million in 2019 to USD 1,377.33 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.99%.

Market Segmentation & Coverage:This research report categorizes the Scaffold Technology to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Scaffold Technology Market studied across Freeze Embryo Testing, Hydrogels, Micropatterned Surface Microplates, Nanofiber-based Scaffolds, and Polymeric Scaffolds.

Based on Application, the Scaffold Technology Market studied across Cancer, Drug Development, Stem cell research, and Tissue Engineering and Clinical Application.

Based on End-User, the Scaffold Technology Market studied across Biotechnology and Pharmaceutical Organizations, Hospitals and Diagnostic Centers, and Research Laboratories and Institutes.

Based on Geography, the Scaffold Technology Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Scaffold Technology Market including 3D Biomatrix, 3D Biotek LLC, 4titude, Akron Biotech, Akron Biotech, Avacta Life Sciences Limited, Becton, Dickinson and Company, Corning Incorporated, Matricel GmbH, Medtronic PLC, Merck KGaA, Molecular Matrix, Inc., Molecular Matrix, Inc., Nanofiber Solutions, NuVasive, Inc., Pelobiotech, REPROCELL, Inc., Tecan Trading AG, Thermo Fisher Scientific, Inc., and Vericel Corporation.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Scaffold Technology Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Scaffold Technology Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Scaffold Technology Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Scaffold Technology Market?4. What is the competitive strategic window for opportunities in the Global Scaffold Technology Market?5. What are the technology trends and regulatory frameworks in the Global Scaffold Technology Market?6. What are the modes and strategic moves considered suitable for entering the Global Scaffold Technology Market?Read the full report: https://www.reportlinker.com/p05989770/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More:

Scaffold Technology Market Research Report by Product, by Application, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19 -...

Read more
New study on CRISPR: the stake of unintended consequences in embryos – BioNews

23 November 2020

A recent paper published in the journalCell revealed the cautionary finding that unwanted changes are introduced after modifying genesin human embryos with CRISPR/Cas9. The study, led by Dr Dietrich Egli, assistant professor of developmental cell biology at Columbia University Vagelos College of Physicians and Surgeons, tested theeffects of CRISPR-based genome editingon embryos carrying a mutationin a gene called EYS (eyes shut homolog) which could lead to hereditary blindness. It shows that applying this potent approachto repair a blindness-causing gene in the formation of an early embryo discards the whole chromosome, or a considerable portion of it, and that the loss of the chromosome is widespread.

CRISPR-based genome editing has revolutionised molecular life sciences. It allows scientists to perform accurate modifications in the genomes of living tissues and may lead to new medical therapies such as innovative cancer treatments and curing hereditary illnesses. In October 2020, CRISPR discoverers (Professors Emmanuelle Charpentier of Max Planck Institute for Infection Biology, Germany, and Jennifer Doudna of University of California, Berkeley) were jointly awarded the Nobel Prize in chemistry.

However, like most innovative techniques, there are currently technical challenges. For example, it is possible to produce so-called off-target effects, where edits are performed in the wrong area. Researchers are still unsure as to how this might affect patients. Another concern is mosaicism, where some cells carry the edit but others do not. Such changes performed to sperm,egg and embryos can be passed to subsequent generations. In the second international summit on human genome editing, there was broad agreement among the experts in attendance that these risks are high.

Despite these serious concerns, in December 2018, Dr He Jiankui shocked the world by announcing that the first babies had been born with altered genomes (see BioNews 978). His work has attracted a backlash from the international scientific community and various governments. Dr He has been sentenced to three years in jail and fined for performing 'illegal medical practices'.

The new research indicates that CRISPR genome editing is currently not ready for clinical application to correct mutations in this early phase of human development. These findings should deter premature clinical use of genome editing on embryos. Thus, using CRISPR to edit the genomes of embryos is a far-off reality.

Due to the serious ethical concerns, the US government does not allow the use of federal funds to perform research on human embryos. The experiment was sponsored by private funding (the New York Stem Cell Foundation and the Russell Berrie Foundation programme). In Australia, section 15 of the Prohibition of Human Cloning for Reproduction Act 2002 prohibits a person from altering the genome of a human embryo in such a manner that the change is heritable by its descendantsandthe person intended this to be so. The penaltyfor this offence is imprisonment for 15 years.

We need to guide responsible and ethical research to achieve safe and effective use. In November 2020, the members of the International Society for Stem Cell Research (ISSCR) task force were charged with revising the2016 ISSCR Guidelines (the Guidelines for Stem Cell Research and Clinical Translation). The ISSCR is the largest stem cell organisation in the world. As a contribution to the developing and controversial stem cell field, this organisation has developed guidelines that address the global diversity of ethical, legal, ethical, cultural and political perspectives related to stem cell research and its translation to clinical application. The guidelines underscore widely shared principles that call for rigour, oversight and transparency. Strict adherence to these principles assures that such cutting-edge research is being conducted with integrity and that innovative medical treatments are evidence-based. Recent advances in this field include innovations in genome editing, organoidsand chimeras. Responding to these various developments in science, the updates will encompass a broader and more expansive scope of research and clinical endeavour, imposing rigour on every stage of the study, addressing the cost of regenerative medicine products and stressing the need for precise and effective public communication.

The persuasive ISSCR Guidelines have been adopted by some scientists, clinicians and institutions around the world. While mere guidelines do not supersede local laws, they could inform the interpretation as well as the development of local laws and provide guidance for research practices not covered by the law. As these guidelines will be updated soon, it is important that they do not encourage the clinical application of the CRISPR approach on genome-editing human embryos for the time being.

Original post:

New study on CRISPR: the stake of unintended consequences in embryos - BioNews

Read more
Post-doctoral Fellow in Computational Stem Cell Biology job with THE UNIVERSITY OF HONG KONG | 234737 – Times Higher Education (THE)

Work type:Full-timeDepartment:School of Biomedical Sciences (22600)Categories:Academic-related Staff

Applications are invited for appointment asPost-doctoral Fellow in Computational Stem Cell Biology (several posts) in the School of Biomedical Sciences(Ref.:502657), to commence as soon as possible for one to three year(s), with the possibility of renewal subject to satisfactory performance.

The selected candidates will work in a company incorporated by the University of Hong Kong that was established to administer and support the Universitys innovation endeavors. They will conduct research in a computational lab and closely work with experimental lab(s).The specific project will be discussed and determined between each candidate and the Principal Investigator together.

Applicants should have a Ph.D. degree in Bioinformatics, Genetics, Computational Biology or other relevant quantitative disciplines, and in-depth experience in at least one of the programming languages for scientific computing, for example, Python, R, Perl, C/C++ and JAVA.Research experience in stem cells, regenerative medicine, cancer, heart disease, liver disease, immunology or drug screening would be an advantage.Preference will be given to those with expertise in bioinformatics and computational biology, and with strong interests in translational research utilizing next-generation sequencing and single-cell sequencing to study any of the above research areas.The ability to work independently, participate in highly collaborative projects, and contribute intellectually to research development are requisites.Applicants should also be highly motivated individuals with good verbal and written communication skills in English.

A competitive salary commensurate with qualifications and experience will be offered.

The University only accepts online applications for the above posts. Applicants should apply online and upload an up-to-date C.V.Review of applications will start from December 4, 2020 and continue untilDecember 30, 2020, or until the posts are filled, whichever is earlier.

See the article here:

Post-doctoral Fellow in Computational Stem Cell Biology job with THE UNIVERSITY OF HONG KONG | 234737 - Times Higher Education (THE)

Read more